Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis. Psoriasis impacts on physical and psychological well‐being; improvements in health‐related quality of life (HRQoL) with etanercept in psoriasis are well documented. OBJECTIVE: To evaluate HRQoL with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenzuela, F., Paul, C., Mallbris, L., Tan, H., Papacharalambous, J., Valdez, H., Mamolo, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108430/
https://www.ncbi.nlm.nih.gov/pubmed/27271195
http://dx.doi.org/10.1111/jdv.13702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108430/
https://www.ncbi.nlm.nih.gov/pubmed/27271195
http://dx.doi.org/10.1111/jdv.13702

Ejemplares similares